Iovance Biotherapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report5 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+43.09%
vs ±17.9% implied · ×2.40
shaded = implied · ▲▼ = realized
Iovance Biotherapeutics has 13 disclosed suppliers and 0 disclosed customers in SEC filings.
SentenceAdditionally, we partner with American Red Cross, or ARC, to operate our facility to produce feeder cells for TIL manufacturing.
IOVA 10-Kaccession 0001104659-26-018899
SentenceFor example, BI carries out the processing, manufacturing, and supply of Proleukin ® pursuant to a manufacturing and supply agreement, which includes a two-year notice of termination provision.
IOVA 10-Kaccession 0001104659-26-018899
SentenceIn May 2023, as part of the Acquisition from Clinigen, we inherited a manufacturing and supply agreement with Boehringer Ingelheim Biopharmaceuticals GmbH, to carry out the processing, manufacturing, and supply of Proleukin ® in unlabeled vials through October 2025.
IOVA 10-Kaccession 0001104659-26-018899
SentenceWe are required to pay substantial royalties and lump sum benchmark payments under our license or acquisition agreements with the NIH, Novartis, Clinigen, and Cellectis, and we must meet certain milestones to maintain our license rights;
IOVA 10-Kaccession 0001104659-26-018899
SentenceIn December 2019, we entered into a research collaboration and exclusive worldwide license agreement for gene-editing technology from Cellectis, a clinical-stage biopharmaceutical company, to develop genetically edited TIL cell therapies, including a PD-1 inactivated product that we refer to as IOV-4001.
IOVA 10-Kaccession 0001104659-26-018899
SentenceWe are required to pay substantial royalties and lump sum benchmark payments under our license or acquisition agreements with the NIH, Novartis, Clinigen, and Cellectis, and we must meet certain milestones to maintain our license rights;
IOVA 10-Kaccession 0001104659-26-018899
SentenceIn May 2023, we acquired the worldwide rights to Proleukin ® from Clinigen Holdings Limited, Clinigen Healthcare Limited, and Clinigen, Inc., which we refer to collectively as Clinigen.
IOVA 10-Kaccession 0001104659-26-018899
SentenceCurrently our products and product candidates are manufactured internally at the i CTC and previously externally by Minaris Advanced Therapies, Inc., or Minaris, and the H. Lee Moffitt Cancer Center, or Moffitt.
IOVA 10-Kaccession 0001104659-26-018899
SentenceWe have a Cooperative Research and Development Agreement, or CRADA, with the NCI for the development of adoptive cell immunotherapies in multiple solid tumor types, including bladder, lung, and triple-negative breast cancers; Human Papilloma Virus, or HPV, associated cancers and a broad range of epithelial cancers.
IOVA 10-Kaccession 0001104659-26-018899
SentenceWe entered into a patent license agreement, or the Patent License Agreement, with the NIH in 2011.
IOVA 10-Kaccession 0001104659-26-018899
SentenceIn November 2016, we entered manufacturing services agreements, or MSAs, with WuXi Advanced Therapies, Inc., and its parent company WuXi Apptec, Co. Ltd (collectively, "WuXi").
IOVA 10-Kaccession 0001104659-26-018899
SentenceCurrently our products and product candidates are manufactured internally at the i CTC and previously externally by Minaris Advanced Therapies, Inc., or Minaris, and the H. Lee Moffitt Cancer Center, or Moffitt.
IOVA 10-Kaccession 0001104659-26-018899
—
—
Linked news
NewsIovance Biotherapeutics, Inc.
8.45
Expected move
Inputs8Q avg ±26.6%·×0.54·cheap
spot 8.48exp Nov 6ATM strike 8.5ATM straddle 1.43IV 152%